Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hTERT peptide–MHC complex is a cell-surface protein complex formed when peptides derived from human telomerase reverse transcriptase (hTERT), a protein highly expressed in the majority of human cancers but not in most normal somatic tissues, are processed and loaded onto major histocompatibility complex (MHC) class I molecules within a cell. These complexes are then exported to the cell surface, where they are recognized by the T cell receptor (TCR) on cytotoxic T lymphocytes, providing a mechanism for immune surveillance and enabling targeted immunotherapies. The hTERT peptide–MHC complex serves as a tumor-specific antigen, making it an attractive target in cancer immunotherapy strategies including TCR-engineered T cells, TCR-like antibodies, and peptide vaccines. Recognition is typically HLA allele-restricted (often HLA-A2 or similar), and the immune response can lead to selective lysis of hTERT-positive cancer cells. The antigen is not entirely tumor-specific, as low-level hTERT expression occurs in certain normal stem cells, leading to a potential but limited risk of off-tumor toxicity. Peptide–MHC complexes such as this one represent a class of immunological targets with high specificity and potential utility in diagnostics, patient monitoring, and therapeutic intervention for a wide range of tumors, and advancing the concept of precision immuno-oncology.
Recognition by T cell receptor (TCR) on cytotoxic T lymphocytes, leading to immune-mediated cell killing Targeting by TCR-like monoclonal antibodies or cellular therapies engineered to recognize the specific complex, resulting in direct tumor cell lysis Vaccination to elicit endogenous T cell responses to hTERT-derived peptides presented by MHC class I molecules
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human telomerase reverse transcriptase peptide–major histocompatibility complex class I complex (hTERT peptide–MHC complex).